Peptide receptor radionuclide therapy (PRRT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who progress after surgical resection. Among 237 analyzed patients, those receiving PRRT experienced a median PFS of 32.4 months compared to 11.0 months for those who did not (p < 0.001). Median OS was also longer at 49.8 months versus 38.4 months (p = 0.009), supporting PRRT as a beneficial treatment approach.
Journal Article by Borbon LC, Sherman SK (…) Howe JR et 9 al. in Ann Surg Oncol
© 2024. Society of Surgical Oncology.